Alterity Therapeutics (ATHE) Receivables (2009 - 2025)

Alterity Therapeutics' Receivables history runs 17 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• On a quarterly basis, Receivables rose 20.86% year-over-year to $4.5 million in Q4 2025; TTM through Dec 2025 was $4.5 million, a 20.86% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, down 5.32% from the prior year.
• Receivables advanced to $4.5 million in Q4 2025 per ATHE's latest filing, from $2.5 million in the prior quarter.
• Across five years, Receivables topped out at $4.6 million in Q4 2022 and bottomed at $40416.8 in Q2 2024.
• The 5-year median for Receivables is $3.6 million (2022), against an average of $3.1 million.
• Across the five-year window, Receivables surged 8095.97% in 2021 and slumped 97.44% in 2023, its largest moves.
• Year by year, Receivables stood at $4.6 million in 2021, then advanced by 1.95% to $4.6 million in 2022, then declined by 16.22% to $3.9 million in 2023, then retreated by 4.58% to $3.7 million in 2024, then gained by 20.86% to $4.5 million in 2025.
• Per Business Quant, the three latest ATHE Receivables figures stand at $4.5 million (Q4 2025), $2.5 million (Q2 2025), and $3.7 million (Q4 2024).